Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Wenjiang District, Chengdu, has secured a Class A "Radiation Safety License" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&D platforms.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。